W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE; STENT, SUPERFICIAL FEMORAL ARTERY
|
Back to Search Results |
|
Model Number VBJR052502A |
Device Problem
Detachment of Device or Device Component (2907)
|
Patient Problems
Stenosis (2263); No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 05/12/2022 |
Event Type
malfunction
|
Manufacturer Narrative
|
Cbas® heparin surface incorporates cbas-heparin manufactured from heparin sodium apl, which in covalently bound to the device surface and is essentially|non-eluting.
|
|
Event Description
|
The following information was reported to gore: on (b)(6) 2022, a gore® viabahn® endoprosthesis (vsx device) was intended for use in the left superficial femoral artery for treatment of stenosis.After the device was successfully implanted, the physician removed the delivery catheter.Upon removal of the delivery catheter it was discovered that the distal tip had separated from the catheter inside the patient.An angiogram was performed and the distal tip was located in the implanted device.The decision was made to advance an additional 5mm x 5cm vsx device and pin the distal tip to the wall of the previously implanted vsx device.A final angiogram was performed to verify that the distal tip was pinned against the wall and the procedure was completed.The patient did not experience any adverse consequences.
|
|
Manufacturer Narrative
|
Section h6 updated to reflect completion of investigation.Manufacturing records were reviewed, and the device met all pre-release specifications.The cause of the reported primary device failure mode, distal tip separation during removal, could not be confirmed.No items were returned for evaluation; however, the device serial number was provided allowing for a review of the bonding process for the device.Review of process data yielded no evidence of a missing distal tip bond.Further information regarding this event was requested by gore, but no further information has been reported, therefore this investigation is considered complete.
|
|
Manufacturer Narrative
|
Revised h6: health effect - clinical code and investigation findings code.
|
|
Search Alerts/Recalls
|
|
|